US › Healthcare

Evotec SE ADR (EVO)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.38-2.82%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$145.9M

Revenue YoY

-14.8%

Net profit

$-47.4M

EPS

$-0.13

EPS estimate

$-0.04

Net margin

-32.5%

EPS came in at -0.13 against a street estimate of -0.04 — a miss of 225.0%.

Key statistics

Market cap

$478.0M

Forward P/E

19.6

P/B

0.73

Book value

$2.09

EPS (TTM)

$-0.64

52-week high

$4.27

52-week low

$1.33

50-day MA

$1.78

200-day MA

$2.65

Beta

1.27

Analyst view

Analysts rate Evotec SE ADR a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $4.20.

Shareholding

Insiders

0.01%

Institutions

0.81%

Largest institutional holders

Fund	Stake
DCF Advisers, LLC	0.30%
WCM Investment Management	0.19%
ABC arbitrage SA	0.10%
Optiver Holding B.V.	0.09%
Morgan Stanley - Brokerage Accounts	0.06%
LPL Financial Corp	0.05%
OLD MISSION CAPITAL LLC.	0.01%
Pathstone Holdings LLC	0.01%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Evotec SE ADR — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.